DURHAM, NC--(Marketwired - March 11, 2014) - DPx Holdings B.V. (DPx), privately owned by JLL Partners and Royal DSM, today launched as a leading global contract development and manufacturing ...

Based on promising results, the biotech IMV has moved into phase 2b trials with a cancer vaccine composed of survivin epitopes that uses the company’s proprietary delivery system to elicit persistent ...

DURHAM, NC--(Marketwired - October 01, 2014) - DPx Holdings B.V., privately owned by JLL Partners and Royal DSM, is pleased to announce the renaming of its DSM Fine Chemicals business unit to DPx Fine ...

BioVaxys Technology ( (TSE:BIOV)) just unveiled an announcement. BioVaxys’ 2025 corporate review highlights the integration of the DPX platform into its operations and a strategic shift toward organic ...

Once you start toting a knife in your EDC, you’ll wonder how you ever lived without it. Cutting, prying, and oh-so-important meat-slicing — you’ve never had it so good. There are plenty of fantastic ...

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against ...

$2.65 billion transaction combines the capabilities and expertise of Patheon and DSM Pharmaceutical Products to create industry powerhouse Durham, N.C. — (March 11, 2014)—DPx Holdings B.V. (DPx), ...

Durham, N.C. — (October 1, 2014)—DPx Holdings B.V., privately owned by JLL Partners and Royal DSM, is pleased to announce the renaming of its DSM Fine Chemicals business unit to DPx Fine Chemicals™.